Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network

Lik Thai Lim¹, FRCoPhth, Seen Nee Chia¹, MBChB, Elliott Yann Ah-kee², MBChB, Nejia Chew³, MBChB, Manish Gupta¹, FRCS

ABSTRACT The Diabetic Retinopathy Clinical Research Network (DRCR.net) performs studies on new treatments for diabetic retinopathy. This review aims to summarise recent findings from DRCR.net studies on the treatment of diabetic macular oedema. We performed a PubMed search of articles from the DRCR.net, which included all studies pertaining to the treatment of diabetic maculopathy. The main outcome measures were retinal thickening as assessed by central subfield thickness on optical coherence tomography and improvement of visual acuity on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Findings from each study were divided into modalities of treatment, namely photocoagulation, bevacizumab, triamcinolone, ranibizumab and vitrectomy. While modified ETDRS focal/grid laser remains the standard of care, intravitreal corticosteroids or anti-vascular endothelial growth factor agents have also proven to be effective, although they come with associated side effects. The choice of treatment modality for diabetic macular oedema is a clinical judgement call, and depends on the patient’s clinical history and assessment.

INTRODUCTION

The Diabetic Retinopathy Clinical Research Network (DRCR.net) performs multicentre clinical research studies on diabetic retinopathy. It is funded by the National Eye Institute and consists of almost 200 clinical sites distributed throughout the United States. The network, which represents a powerful resource to rapidly assess new treatments, has completed a number of studies that have dramatically enhanced the management of diabetic retinopathy. Secondary manuscripts from assorted DRCR.net studies have also provided useful information on both patient care and study design. A complete list of publications is available from the DRCR.net website.

Diabetic retinopathy is a major cause of blindness in the working-age group (i.e. 25–65 years). Clinically significant diabetic macular oedema (DMO) is the commonest cause of moderate visual loss. Wild et al estimated the worldwide prevalence of diabetes mellitus to be 2.8%.¹ The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), a population-based study in southern Wisconsin, estimated that the prevalence of DMO after 20 years of known diabetes mellitus was about 28% in both type 1 and type 2 diabetes mellitus.² The incidence over a ten-year period was reported to be 20.1% in the younger-onset group (before age 30 years), 25.4% in the older-onset group taking insulin and 13.9% in the older-onset group not taking insulin.³ The 25-year cumulative incidence in type 1 diabetes mellitus was found to be 29% and 17% for macular oedema and clinically significant macular oedema, respectively.⁴⁻⁵

DMO is defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) as the presence of: (a) retinal thickening at or within 500 µm of the centre of the macula; or b) hard exudates that are associated with adjacent retinal thickening at or within 500 µm of the centre of the macula; or (c) zone(s) of retinal thickening of one-disc area or larger, any part of which is within the one-disc diameter of the centre of the macula.⁶ Traditionally, DMO is further classified as focal or diffuse based on the leakage pattern on fundus fluorescein angiography (FFA). The DRCR.net studied this classification using time domain optical coherence tomography (OCT) (Stratus OCT-3; Carl Zeiss, Jena, Germany). Browning et al’s classification of DMO into focal or diffuse did not explain the variations in visual acuity (VA) or responses to treatment, and there are also inconsistencies in clinical examination, colour fundus photography, FFA and OCT, which were further complicated by hybrid definitions.⁷ The hybrid definitions have been used to define diffuse DMO, but not focal DMO. These definitions can be categorised into subgroups based on: (a) clinical examination and FFA criteria; and (b) clinical examination, FFA and OCT criteria.

Extending the concept of focal and diffuse by assessing the number of thickened subfields on OCT showed only modest correlation with baseline acuity but no correlation with subsequent changes in acuity, although OCT has a greater likelihood of detecting cystoid abnormalities compared to FFA.⁷⁻⁸ OCT and fundus photograph both provide complementary information and have moderate correlation in assessing retinal thickening in DMO. However, this cannot be a surrogate for VA,⁹ as there is a wide range of acuity for a given degree of retinal oedema even following laser treatment.⁹⁻¹⁰

This review aims to summarise recent findings from DRCR.net studies on the treatment of DMO. The primary outcomes are
reduction in thickening assessed by central subfield thickness (CST) on Stratus OCT-3 and improvement of VA on the ETDRS chart.

**METHODOLOGY**

We searched articles from the DRCR.net indexed on PubMed and included all studies pertaining to treatment of diabetic maculopathy. The results were divided into the modality of treatment used in each study. These modalities of treatment were photocoagulation (including focal or grid photocoagulation and scatter photocoagulation), bevacizumab, triamcinolone, ranibizumab and vitrectomy. The outcomes of all the studies according to treatment modality for DMO are summarised in Table 1.

**PHOTOCOAGULATION**

**Focal/grid photocoagulation**

Focal or grid photocoagulation has been the standard of care in the management of DMO for the past 25 years (as defined by ETDRS). All DRCR.net trials involving laser utilised modified ETDRS (mETDRS) focal/grid photocoagulation, which is the technique widely adopted in current clinical practice. The original ETDRS technique used 50–200 micron spot size argon green or blue-green wavelength, and the “above threshold but less intense than PRP (panretinal photocoagulation) burns” as endpoints. Such intense treatment can result in retinal pigment epithelium atrophy from laser scar expansion, secondary choroidal neovascular membranes and subretinal fibrosis. The gentler mETDRS approach limits the spot size to 50 micron, utilises yellow or green wavelengths, and applies less intense burns (light grey) for the endpoint. Also, grid treatment is applied to areas of thickened retina (and areas of retinal non-perfusion), and direct focal treatment is applied to leaking microaneurysms, but blanching is not required as long as light grey colour change is produced in the subadjacent retinal pigment epithelium.

In a 2007 randomised trial, Fong et al evaluated a different approach using mild macular grid (MMG). This technique differs from mETDRS in that the burns are lighter and more diffused and distributed throughout the macula in both the areas of thickened and unthickened retina; the microaneurysms are also not directly photocoagulated. Subjects had baseline ETDRS VA letter score ≥ 19 (≥ 20/400). At one year, both MMG and mETDRS led to a reduction in retinal thickening, but mETDRS showed a significantly greater reduction in retinal thickening and greater resolution of DMO (p = 0.01). Despite this, VA outcomes between the two approaches were similar. Mean change in VA was 0 letters in mETDRS and −2 letters in MMG, with improvement of ≥ 15 letters in 7% and 5%, respectively, and deterioration of ≥ 15 letters in 7% and 10%, respectively. Re-treatment rates of the two approaches at four monthly intervals were also similar, with 33% of mETDRS and 41% of MMG re-treated once, and 25% and 27%, respectively, re-treated twice. In a nutshell, the MMG approach showed no benefit over mETDRS; thus, the authors recommended that mETDRS focal photocoagulation remain the standard approach for treating DMO.

In terms of predicting the VA outcomes following mETDRS laser treatment, an analysis by Aiello et al in 2010 found greater improvement in eyes that had worse baseline acuity and, conversely, further worsening in eyes that had better baseline acuity or greater retinal thickness. Other factors such as systemic control, OCT morphology, retinopathy severity and prior photocoagulation were not associated with VA outcome. Furthermore, while eyes that initially worsened were more likely to subsequently improve, eyes with acuity ≥ 20/32 were subsequently more likely to worsen due to the ceiling on achieving additional substantial improvement. This ceiling refers to the amount of improvement that can be achieved when VA is only slightly reduced. In eyes with non-centre-involved clinically significant DMO, mETDRS treatment is recommended, as it was found to be effective in stabilising VA and retinal thickness, as well as in decreasing FFA leakage area. At one year, 75% of patients retained VA ≥ 20/25 from a baseline of 20/40−1 or better.

The response to laser is gradual and improvement is usually observed after four months. An observational study of a single mETDRS photocoagulation session involving subjects with ETDRS VA letter score ≥ 24 (≥ 20/320) demonstrated that four months after the treatment, 28% had definite reduction but not resolution of oedema, of which 23%–63% would continue to improve without additional treatment over the next four months. Eyes with greater thickening (≥ 400 microns) had a higher frequency of continued improvement. Additional laser treatment was deferred if the VA letter score improved by ≥ 5 letters, or if OCT CST decreased by ≥ 10% compared with the findings four months prior. The study concluded that meeting VA deferral criterion alone at four months is poorly predictive of the possibility of subsequent deferral of re-treatment through 48 weeks of follow-up, as 69% required re-treatment after the four-month visit.

**Scatter photocoagulation**

The development of DMO following PRP was compared with PRP given in one or four sittings. Subjects had early proliferative diabetic retinopathy (PDR) or severe non-proliferative diabetic retinopathy (NPDR), baseline OCT-3 CST < 300 microns, and ETDRS VA letter score ≥ 73 (≥ 20/32). PRP was delivered with a total of 1200–1600 burns in either one sitting or four sittings at four weekly intervals, with 300 burns applied in each of the first two sittings. Both retinal thickness and VA in both groups worsened initially; the changes were greater when more burns were applied in a single sitting. However, they improved over time such that at subsequent visits, more improvement was observed in the one-sitting group compared with the four-sitting group because of the shorter time interval from the last laser sitting. Overall, there was no difference in DMO with PRP delivered in one or four sittings, and both groups were equally controlled in terms of their proliferative disease. However, PRP given in multiple sittings seems more favourable, as it minimises discomfort and reduces the risk of adverse effects such as cystoid macular oedema.
BEVACIZUMAB
Bevacizumab is a humanised monoclonal antibody that competitively inhibits all vascular endothelial growth factor (VEGF)-A isoforms within the extracellular space. Currently approved by the Food and Drug Administration (FDA) for the treatment of metastatic breast cancer, metastatic colorectal cancer and non-small cell lung cancer, bevacizumab is also used as an off-label treatment for neovascular age-related macular degeneration, retinal vein occlusion and DMO. The short-term outcomes of intravitreal bevacizumab alone or in combination with mETDRS photocoagulation versus photocoagulation alone were evaluated in a phase II trial.\(^{(19)}\) Subjects who had baseline ETDRS VA letter scores of 24–78 (20/320 to 20/32) were followed up for three months. It was found that, compared with photocoagulation, bevacizumab resulted in a greater reduction in central retinal thickness at three weeks, but only gradual improvement was observed with photocoagulation alone, such that no difference was seen after three weeks. Half of the eyes treated with bevacizumab responded with more than 11% reduction in retinal thickness, although this initial reduction at three weeks decreased after three to six weeks. However, there was a constant one-line improvement in VA with bevacizumab compared to photocoagulation. The study also showed no difference in outcomes between bevacizumab doses of 1.25 mg and 2.5 mg. Combined treatment with bevacizumab and photocoagulation did not show any additional short-term benefit.

TRIAMCINOLONE
A Cochrane review suggests that intravitreal steroids play a role in persistent or refractory DMO.\(^{(17)}\) The DRCR.net studies used a preservative-free form of triamcinolone, and results have been discouraging due to unsustainable short-term efficacy and long-term side effects, particularly dose-related intraocular pressure (IOP) elevation and cataract. A randomised trial by the DRCR.net in 2008\(^{(18)}\) evaluated the effect of two doses of intravitreal triamcinolone acetoneid (1 mg and 4 mg) as compared to mETDRS photocoagulation. Participants had baseline ETDRS VA letter scores of 24–73 (20/320 to 20/40).\(^{(19)}\) It was found that, compared with photocoagulation, triamcinolone is less effective and has greater adverse effects at two years, with the results consistent even at three years.\(^{(19)}\) Eyes treated with triamcinolone 4 mg showed significant initial VA improvement and reduction in retinal thickness at four months, but these levelled out at one year. By the second and third year, VA in the triamcinolone group was inferior to the group that received photocoagulation, even after taking into account lens changes. Retinal thickness paralleled the acuity changes, with less reduction than laser but no difference between the two triamcinolone doses.

Major adverse events are two times greater with the use of triamcinolone 4 mg compared to triamcinolone 1 mg. IOP elevation occurred in 40%–50% of eyes treated with triamcinolone 4 mg compared with 20% in eyes treated with triamcinolone 1 mg, with 13% and 6%, respectively, requiring IOP-lowering medications by two years. Four eyes in the triamcinolone 4 mg group required glaucoma procedures (two eyes had filtering procedure, one had laser trabeculectomy and one had ciliary body destruction). Cataract surgery was performed in 51%–59% of eyes treated with triamcinolone 4 mg over two years compared with 23% in eyes treated with triamcinolone 1 mg.\(^{(18)}\) The three-year cumulative probability of development of cataract increased to 83% in eyes treated with triamcinolone 4 mg. Hence, although triamcinolone seemed more effective than laser alone in pseudophakic eyes, there is frequently an increased risk of IOP elevation. The rate of endophthalmitis associated with intravitreal triamcinolone injections was reported to be as low as 0%–0.05%; this was achieved with the use of a protocol that included topical povidone-iodine, a sterile lid speculum, topical anaesthetic and post-injection topical antibiotics four times a day for three days (without antibiotic prophylaxis).\(^{(20,21)}\)

Another trial conducted by Elman et al\(^{(22)}\) in 2011 reported findings from a two-year follow-up of a previously reported randomised trial evaluating intravitreal ranibizumab 0.5 mg or triamcinolone 4 mg combined with focal/grid laser, compared with focal/grid laser alone for the treatment of DMO. Elman et al showed that a combination treatment of triamcinolone 4 mg and prompt laser resulted in similar reduction in retinal thickening in the first year but not the second year, with comparable VA improvement with ranibizumab.\(^{(22)}\) Among a small number of eyes with the most severe VA loss at baseline (20/200 to 20/320) secondary to DMO, most eyes treated with triamcinolone 4 mg had improvement at two years, but the number was too small (13 eyes) for any meaningful assessment.

Triamcinolone 4 mg also offers additional benefits such as reducing the risks of retinopathy progression and development of vitreous haemorrhage, and lowering the need for PRP over a period of three years.\(^{(18)}\) This effect can be sustained without additional injections.\(^{(23)}\) The incidence of vitreous haemorrhage is lower in spite of any possibility of cataract obscuring the identification of PDR. However, the use of triamcinolone 4 mg to reduce the likelihood of progression of retinopathy is not warranted due to the increased risks of glaucoma and cataract.\(^{(19)}\) In eyes with severe PDR or NPDR, DMO and a ETDRS VA letter score ≥ 24 (≥ 20/320), PRP and concurrent focal/grid laser for DMO with additional single intravitreal injections of triamcinolone 4 mg resulted in better VA and decreased macular oedema for 4–14 weeks.\(^{(24)}\) The efficacy and side effect profile is similar if two intravitreal injections of ranibizumab 0.5 mg were given instead. Even in the short term, the risks are reduced for the development of vitreous haemorrhage, tractional retinal detachment, need for vitrectomy, or requirement of additional focal/grid laser treatment for DMO. Elevation of IOP is more frequent in triamcinolone (17%).\(^{(24)}\) Hence the long-term risks need to be weighed against the short-term benefits.

Limited efficacy and an unfavourable side effect profile were also observed with subtenon injection of triamcinolone. In a phase II study,\(^{(25)}\) anterior and posterior subtenon injection of triamcinolone, either alone or in combination with focal photocoagulation was evaluated in mild DMO. In this study, anterior injection of triamcinolone 20 mg was given beneath the bulbar conjunctiva under the lower lid and posterior injection of triamcinolone 40 mg
was given in the subtenon’s space of the superior temporal quadrant, about 10 mm posterior to the limbus. Participants had baseline ETDRS VA letter scores ≥ 69 (≥ 20/40), a mean acuity letter score of 79 (20/25) and mean OCT CST of 328 microns. No substantial benefit of using peribulbar triamcinolone with or without focal photoagulation in DMO was reported, with good VA noted compared with photoagulation alone. There was reduction in retinal thickening in all treated eyes and worsening of mean acuity letter score of 1–4. The results of anterior and posterior subtenon injections were similar. Combined peribulbar triamcinolone and focal photoagulation resulted in a 50% reduction in the need for re-treatment, as compared with laser treatment alone. However, the authors warned that the investigators were not blinded to the treatment groups. Furthermore, based on the investigators’ judgement, any true benefit of peribulbar triamcinolone for mild DMO is unlikely to exceed a mean improvement of 13 microns in retinal thickness on the grounds of the re-treatment criteria of ≥ 250 microns retinal thickness or macular oedema.32

In terms of the two-year safety profile, anterior peribulbar injection was associated with an increased incidence of IOP elevation and more substantial cataract formation, presumably due to higher steroid levels in the anterior segment with this delivery modality.33 IOP elevation is 4.2 times more likely to occur with anterior peribulbar injection compared to laser, and 2.3 times more likely to occur compared to posterior injection. The rates of IOP elevations with anterior peribulbar triamcinolone were similar to those previously reported for intravitreal triamcinolone, with a third having IOP elevation ≥ 10 mmHg and requiring IOP-lowering medications, although none had required glaucoma surgery. Cataract progression or extraction was significantly higher in anterior injection (62%) compared with posterior injection (38%) and laser (27%). Posterior injection carries a higher risk of ptosis compared with anterior injection (12% vs. 6%); there is, however, no risk of ptosis in laser alone. As adverse effects may not be seen until the second year of treatment, long-term follow-up is advised in eyes treated with peribulbar corticosteroid.

**RANIBIZUMAB**

Like bevacizumab, ranibizumab is also a VEGF inhibitor administered intravitreally. It was licensed in the European Union for the treatment of DMO in March 2011 following the outcomes of company-sponsored RESOLVE and RESTORE studies. In the phase II RESOLVE study, ranibizumab at doses ≤ 1.0 mg (three monthly injections and subsequently as needed) was found to be more effective than sham injections in improving functional and anatomical outcomes in patients with DMO.34 In the phase III RESTORE study, ranibizumab 0.5 mg (three monthly injections and subsequently as needed), either alone or combined with laser therapy, was shown to be more effective than laser alone in improving functional and anatomical outcomes in patients with DMO.35

A phase III DRCR.net study29 evaluated the outcome of intravitreal ranibizumab 0.5 mg or triamcinolone 4 mg combined with focal/grid laser compared with focal/grid laser alone for treatment of DMO. Subjects in this study had ETDRS VA letter scores of 24–78 (20/320 to 20/32). Ranibizumab with prompt/deferred (after 24 weeks) laser resulted in superior VA and central retinal thickness at one and two years, as compared with prompt laser alone. Significantly more eyes gained substantial vision (50% of eyes had improvement of ≥ 10 letter scores from the baseline) and significantly fewer eyes lost substantial vision (4%) (p = 0.01). Improvement in eyes treated with ranibizumab mostly occurred by two months and continued to improve through one year, stabilising thereafter. Ranibizumab also reduced the progression of diabetic retinopathy, the development of vitreous haemorrhage or the need for PRP, with the effects sustained for up to two years. The median number of ranibizumab injections was eight in one year. Treatment with combined ranibizumab and deferred laser did not obviate the need for focal/grid laser; one-third of eyes required at least one laser treatment.36 The results of a three-year follow-up study of the same randomised controlled trial suggest that focal/grid laser treatment at the initiation of intravitreal ranibizumab was no better, and possibly worse for vision outcomes, than deferring laser treatment for ≥ 24 weeks in eyes with DMO involving the fovea and those with vision impairment. Ongoing follow-up of this protocol will continue over a five-year period.37

An analysis of VA outcomes and OCT thickness following intravitreal ranibizumab did not identify any factors associated with poor outcomes at one year following treatment, due to the low number of participants with vision loss or increase in CST.38 However, this study identified possible predictors of better visual outcomes, including CST evolution, younger age, less severe diabetic retinopathy on clinical examination and absence of surface wrinkling retinopathy.39 This can be useful when balancing the risks and benefits of ranibizumab for centre-involved DMO.

Ranibizumab injections are uncommonly associated with infectious endophthalmitis (0.8%) and a theoretical risk of traction retinal detachment in PDR (0.3%). There is a 9% increased risk of IOP elevation for ranibizumab and a cumulative percentage of 14% that undergo cataract surgery over two years, but both incidences are much lower compared with that for triamcinolone 4 mg. Furthermore, ranibizumab has a longer-term outcome of five years, which reinforces that ranibizumab should be considered in DMO.30

Another DRCR.net study assessed the use of ranibizumab in eyes with severe NPDR or PDR and DMO with ETDRS VA letter score ≥ 24 (≥ 20/320).40 In eyes that received PRP and concurrent focal/grid laser for DMO, two additional injections of intravitreal ranibizumab 0.5 mg enhanced VA improvement and decreased macular oedema by 14 weeks. VA improvement usually occurred within one month, with no difference noted between PRP performed in single or multiple sittings. In addition, ranibizumab-treated eyes were less likely to develop vitreous haemorrhage and tractional retinal detachment, or require vitrectomy or additional focal/grid laser treatment for DMO. The side effect profile is similar in the short and long term.

As with triamcinolone injections, the rate of endophthalmitis is reportedly low, i.e. 0.09% per injection or 0.65% per eye, and
the overall incidence ranged from 0.4% to 0.8% with intravitreal ranibizumab.\textsuperscript{(29,32,33)} Cultures isolated were mainly coagulase negative \textit{Staphylococcus viridans} with one case of \textit{Streptococcus viridans} reported. There was no difference in systemic adverse events such as cardiovascular or cerebrovascular events compared with sham injections or triamcinolone in all studies.\textsuperscript{(29,32,33)} This information may be useful when discussing the risks and benefits of different treatment modalities with patients who have cardiovascular comorbidities.

**VITRECTOMY**

In one study, vitrectomy for the treatment of DMO and vitreomacular traction was shown to reduce CTO in most eyes, with 28%–49% experiencing improvement of VA and 13%–31% worsening.\textsuperscript{(34)} The surgical complication rate for vitrectomy was low. The baseline ETDRS VA letter score was 19–63 (20/63 to 20/400) and Stratus OCT retinal CST was > 300 microns. PDR (in two-thirds) and vitreomacular traction were indications for vitrectomy. Standard pars plana vitrectomy was performed via three pars plana sclerotomies, removal of vitreous gel, with peeling of the posterior hyaloid if attached and removal of the peripheral vitreous, leaving only a small residual vitreous skirt; engagement and peeling of the epiretinal membrane (ERM) judged visually significant; and treatment of any peripheral breaks with laser or cryotherapy. Cataract extraction was not performed in conjunction with vitrectomy and 40% received PRP intraoperatively.\textsuperscript{(34)}

Following vitrectomy, VA gains observed at six months are more likely to continue improving, whereas VA loss at six months is less likely to improve. Removal of ERM may favourably affect visual outcome after vitrectomy, reflecting resolution of distorted vision from the ERM rather than resolution of DMO.\textsuperscript{(12)} Central retinal thickness decreased by ≥50% at six months in two-thirds of individuals with baseline OCT central retinal thickness ≥ 250 microns, and half of these eyes had retinal thickness < 250 microns at one year. Eyes with greater CST at baseline tended to have greater reduction in thickness after surgery. Preoperative vitreoretinal abnormalities are associated with somewhat greater reductions in retinal thickness but not with VA outcome. Except for cases with very large decreases in CST of > 350 microns, a given decrease in thickness on OCT was associated with a wide range of changes in VA. Postoperative complications occurred in 18% in the first six months, including vitreous haemorrhage, retinal detachment and endophthalmitis. Most phakic eyes (78%) developed lens changes by six months and half of the studied eyes underwent cataract surgery within one year. Additional DMO treatment with intravitreal corticosteroid, anti-VEGF and macular laser were each given in 26% of the eyes. However, no significant changes in VA or CST were noted between six months and one year following these procedures.\textsuperscript{(34)}

**CONCLUSION**

The DRCR.net is an effective network for research that has facilitated the rapid assessment of new treatments for diabetic retinopathy, DMO and associated conditions without any drug company funding. The trend in the management of DMO continues to evolve. While mETDRS focal/grid laser remains the standard of care due to its safety profile, its gradual effects are superseded by intravitreal corticosteroids or anti-VEGF, which also offer the additional benefit of reducing diabetic retinopathy progression. In the short term, intravitreal ranibizumab and triamcinolone result in greater VA and retinal thickening outcomes. However, these two agents require maintenance with repeated injections and also have longer-term associated side effects and higher costs. Triamcinolone in particular has unfavourable effects such as elevation of IOP and cataract development. Ranibizumab carries a theoretical increased risk of tractional retinal detachment. Vitrectomy with ERM peel improves anatomical structure but has variable VA outcomes. In light of new evidence on the management of DMO, the most suitable modality of treatment would depend on the clinical history and assessment of each case in its own right. The clinician will have to use good clinical judgement in the planning of each case of DMO.

**REFERENCES**

12. Scott IU, Davis BP, Bressler SB, et al; Diabetic Retinopathy Clinical Research Network. Effect of focal/grid photocoagulation on visual acuity...


<table>
<thead>
<tr>
<th>Treatment modality</th>
<th>Study design</th>
<th>Participants</th>
<th>Re-treatment</th>
<th>Outcome</th>
<th>Adverse effects</th>
<th>Authors’ comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Focal/Grid photocoagulation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mETDRS</td>
<td>RCT; 12 mth; 142 subjects&lt;sup&gt;(11)&lt;/sup&gt;</td>
<td>DMO with VA ≥ 19 (≥ 20/400); OCT retinal thickening ≥ 250 μm in CST or ≥ 300 μm in at least one of the four inner subfields; no prior laser or DMO treatment</td>
<td>None: 42%; once: 33%; twice: 25%</td>
<td>Mean decrease of CST: 88 μm*; all subfields within normal range: 23%; mean decrease in DMO area on fundus photo: 0.2 DD*; mean change in VA: 0 letters; gain ≥ 15 letters: 7%; loss ≥ 15 letters: 7%</td>
<td>None</td>
<td>mETDRS remains the standard of care</td>
</tr>
<tr>
<td>mETDRS</td>
<td>Phase II RCT; 12 wk; 19 eyes in laser alone group&lt;sup&gt;(16)&lt;/sup&gt;</td>
<td>DMO with VA 78–24 letters (20/32–20/320); OCT CST ≥ 275 μm; one eye per subject</td>
<td>79%</td>
<td>3 wk median change in CST: +21 μm; 3 wk &lt; 250 μm or ≥ 50% CST reduction: 11%; 12 wk median change in CST: −40 μm; 12 wk &lt; 250 μm or ≥ 50% CST reduction: 21%; 3 wk median change in VA: −2 letters; 12 wk median change in VA: −1 letter; gain ≥ 15 letters: 5%; loss ≥ 10 letters: 5%</td>
<td>Anaemia (1); peripheral vascular disease (2); hypertension (1); worsening renal function (1)</td>
<td>After 3 wk, no difference in retinal thickening but less one line VA compared to bevacizumab</td>
</tr>
<tr>
<td>mETDRS</td>
<td>Observational; 12 mth; 24 subjects&lt;sup&gt;(13)&lt;/sup&gt;</td>
<td>Non-centre-involved DMO: CST &lt; 250 μm and photography assessment of retinal thickness at the centre of the macula graded as ‘none’ or ‘questionable’</td>
<td>–</td>
<td>Median decrease of retinal thickness: 4–12 μm; CST decreased ≥ 25 μm: 18%; mean decrease in DMO area on fundus photo: 0.2 DD; fluorescein leakage: −0.7 DA; decrease ≥ 1 DA fluorescein leakage: 44%; DMO area in fundus photo: +0.21 DA; median change in VA: −1 letter; gain ≥ 5 letters: 18%; loss ≥ 5 letters: 32%</td>
<td>None</td>
<td>mETDRS appropriate in non-centre-involved DMO</td>
</tr>
<tr>
<td>mETDRS</td>
<td>Observational; 24 mth; 115 eyes&lt;sup&gt;(14)&lt;/sup&gt;</td>
<td>DMO with VA ≥ 24 letters (≥ 20/320); CST ≥ 250 μm</td>
<td>21%</td>
<td>Decrease CST ≥ 10% at 16 wk: 47%; gain ≥ 5 letters: 35%, loss ≥ 5 letters: 19%; further decrease CST ≥ 10% after 16 wk: 10%; gain ≥ 5 letters: 35%, loss ≥ 5 letters: 19%</td>
<td>None</td>
<td>In eyes with definite reduction but not resolution of central oedema at 16 wk, 23%–63% continue to improve without further treatment</td>
</tr>
<tr>
<td>mETDRS</td>
<td>Phase III RCT; 2 yr &amp; 3 yr; 330 eyes in laser alone&lt;sup&gt;(12)&lt;/sup&gt;</td>
<td>DMO with VA 73–24 letters (20/40–20/320), OCT thickness ≥ 250 μm</td>
<td>Mean no. of treatment: 2 yr (2.9); 3 yr (3.1)</td>
<td>Median change in CST: 2 yr (−131 μm), 3 yr (−158 μm); median change in VA letters: 4 mth (+2), 2 yr (+4), 3 yr (+8); gain ≥ 15 letters: 2 yr (18%), 3 yr (26%); loss ≥ 15 letters: 2 yr (14%), 3 yr (8%)</td>
<td>Retinal detachment (2), retinal vein occlusion (3), retinal artery occlusion (1), vitrectomy (31), IOP elevation (10%), cataract surgery (13%)</td>
<td>Focal/grid laser is more effective and has fewer side effects than 1 mg or 4 mg triamcinolone</td>
</tr>
</tbody>
</table>

(Contd.)
<table>
<thead>
<tr>
<th>Treatment modality</th>
<th>Study design</th>
<th>Participants</th>
<th>Re-treatment</th>
<th>Outcome</th>
<th>Adverse effects</th>
<th>Authors’ comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>mETDRS</td>
<td>Phase 3 RCT; 1 yr &amp; 2 yr; 293 eyes in sham injection + prompt laser&lt;sup&gt;(22)&lt;/sup&gt;</td>
<td>DMO with VA 78–24 letters (20/32–20/320), OCT CST ≥ 250 μm</td>
<td>Median no. of treatment: 1 yr (3); laser by 48 wk: 26%</td>
<td>Median change in CST: 1 yr (~79 μm), 2 yr (~104 μm); CST &lt; 250 μm and ≥ 25 μm reduction: 1 yr (27%), 2 yr (38%); median change in VA letters: 1 yr (+5), 2 yr (+6); gain ≥ 15 letters: 1 yr (15%), 2 yr (18%); loss ≥ 15 letters: 1 yr (8%), 2 yr (10%); DR progression at 1 yr: improved (22%), worsened (15%)</td>
<td>2 yr: retinal detachment (0); vitreous haemorrhage (9%); elevation of IOP/glaucoma (11%); glaucoma surgery (1%); cataract surgery (12%)</td>
<td>Gradual improvement during the first year with stabilisation thereafter</td>
</tr>
<tr>
<td>Mild macular grid</td>
<td>RCT; 12 mth; 162 eyes&lt;sup&gt;(11)&lt;/sup&gt;</td>
<td>DMO with VA ≥ 19 letters (≥ 20/400); OCT retinal thickening ≥ 250 μm in central subfield or ≥ 300 μm in at least one of the four inner subfields; no prior laser or DMO treatment</td>
<td>None: 33%; once: 41%; twice: 27%</td>
<td>Mean decrease of CST: 49 μm; all subfields within normal range: 17%; mean decrease in DMO area on fundus photo: 0.08 DD; mean change in VA: −2 letters; gain ≥ 15 letters: 5%; loss ≥ 15 letters: 10%</td>
<td>One neurosensory detachment, which resolved after 1 mth</td>
<td>Mild macular grid is not recommended for DMO</td>
</tr>
<tr>
<td>Scatter photocoagulation</td>
<td>RCT; 34 wk; in 1 sitting: 84 eyes; in 4 sittings: 71 eyes&lt;sup&gt;(15)&lt;/sup&gt;</td>
<td>Early PDR or severe NPDR, VA ≥ 73 letters (≥ 20/32), OCT CST &lt; 300 μm</td>
<td>In 1 sitting: 7%; in 4 sittings: 0%</td>
<td>In 1 sitting: Median no. of burns: 1,274; retrobulbar anaesthetic injection: 46%; 3 day median change in CST: +9 μm; 4 wk median change in CST: +13 μm; 17 wk median change in CST: +14 μm; 34 wk median change in CST: +14 μm; 3 day median change in VA: −3 letters; 34 wk median change in VA: 0 letters&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Significant vitreous haemorrhage: 2 eyes in each group</td>
<td>Scatter PRP can be safely administered in a single sitting</td>
</tr>
</tbody>
</table>

<sup>*</sup> Median no. of burns: 1,260; retrobulbar anaesthetic injection: 14%; 3 day median change in CST: +5 μm; 4 wk median change in CST: +5 μm; 17 wk median change in CST: +15 μm; 34 wk median change in CST: +22 μm; 3 day median change in VA: −1 letters; 34 wk median change in VA: −2 letters
<table>
<thead>
<tr>
<th>Treatment modality</th>
<th>Study design</th>
<th>Participants</th>
<th>Re-treatment</th>
<th>Outcome</th>
<th>Adverse effects</th>
<th>Authors’ comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRP in 1–3 sittings + focal/</td>
<td>Phase III study; 14 wk; 123 eyes</td>
<td>DMO with severe NPDR or PDR; VA ≥ 24 letters (≥ 20/320); OCT CST ≥ 250 μm</td>
<td>Additional PRP: 24%; additional DMO Rx: 59%</td>
<td>Median change in CST: 0 μm; CST &lt; 250 μm and ≥ 25 μm reduction: 10%; median change in VA letters: −2; gain ≥ 15 letters: 4%; loss ≥ 15 letters: 15%</td>
<td>56 wk: endophthalmitis (0); retinal detachment (4); vitreous haemorrhage (28); IOP elevation (14); glaucoma surgery (0); cataract surgery (2)</td>
<td>Eyes with centre-involved DMO receiving prompt PRP at the time of focal/grid laser for DMO are more likely to have increased macular oedema and VA loss in the short-term</td>
</tr>
<tr>
<td>grid + sham injections</td>
<td>(24)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.25 mg at 0 + 6 wk; 2.5 mg</td>
<td>Phase 2 RCT, 12 wk; in 1.25 mg at 0 + 6 wk; 22 eyes; in 2.5 mg at 0 + 6 wk; 24 eyes; in 1.25 mg at baseline only; 22 eyes; in 1.25 mg at 0 + 6 wk/laser at 3 wk: 22 eyes</td>
<td>DMO with VA 78–24 letters (20/32–20/320), OCT CST ≥ 275 μm, one eye per subject</td>
<td>In 1.25 mg at 0 + 6 wk: 67%; in 2.5 mg at 0 + 6 wk: 67%; in 1.25 mg at baseline only: 86%; in 1.25 mg at 0 + 6 wk/laser at 3 wk: 75%</td>
<td>1.25 mg at 0 + 6 wk: 3 wk median change in CST: −35 μm*; 3 wk &lt; 250 μm or ≥ 50% CST reduction: 37%; 12 wk median change in CST: −56 μm; 12 wk &lt; 250 μm or ≥ 50% CST reduction: 33%; 3 wk median change in VA: +5 letters; 12 wk median change in VA: +5 letters; gain ≥ 15 letters: 14%; loss ≥ 10 letters: 5% 2.5 mg at 0 + 6 wk: 3 wk median change in CST: −86 μm*; 3 wk &lt; 250 μm or ≥ 50% CST reduction: 38%; 12 wk median change in CST: −47 μm; 12 wk &lt; 250 μm or ≥ 50% CST reduction: 33%; 3 wk median change in VA: +6 letters; 12 wk median change in VA: +7 letters; gain ≥ 15 letters: 13%; loss ≥ 10 letters: 0%</td>
<td>Coagulase negative staphylococcus endophthalmitis (1); transient raised IOP (1); myocardial infarction (2); congestive heart failure (1); elevation of blood pressure (3); death due to pancreatic cancer (1); peripheral vascular disease (1); syncope (1); worsening renal function (3); anaemia (4)</td>
<td>Bevacizumab 1.25 mg or 2.5 mg result in one line VA improvement compared to laser, but no difference in CST after 3 wk; bevacizumab 2.5 mg unlikely to produce greater short-term CST reduction than 1.25 mg; CST reduction at 3 wk plateau or decrease, hence 6 wk injection interval is too long; no short-term benefit or adverse outcomes in combination therapy with laser</td>
</tr>
<tr>
<td>Treatment modality</td>
<td>Study design</td>
<td>Participants</td>
<td>Re-treatment</td>
<td>Outcome</td>
<td>Adverse effects</td>
<td>Authors’ comments</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>---------</td>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td><strong>Triamcinolone</strong></td>
<td>Phase III RCT; 2 yr &amp; 3 yr; 1-mg group: 256 eyes; 4-mg group: 254 eyes (23)</td>
<td>DMO with VA 73–24 letters (20/40–20/320), OCT thickness ≥ 250 μm</td>
<td>1-mg group: mean no. of treatment: 1 yr (2.3); 2 yr (3.5); 3 yr (4.2) 4-mg group: mean no. of treatment: 1 yr (2.1); 2 yr (3.1); 3 yr (4.1)</td>
<td>In 1-mg group: Median change in CST: 2 yr (−74 μm), 3 yr (−103 μm); median change in VA letters: 4 mth (+2), 2 yr (+1), 3 yr (+2); gain ≥ 15 letters: 2 yr (14%), 3 yr (20%); loss ≥ 15 letters: 2 yr (20%), 3 yr (17%) In 4-mg group: Median change in CST: 2 yr (−76 μm), 3 yr (−114 μm); median change in VA letters: 4 mth (+5), 2 yr (+2), 3 yr (+4); gain ≥ 15 letters: 2 yr (17%), 3 yr (21%); loss ≥ 15 letters: 2 yr (20%), 3 yr (16%)</td>
<td>1-mg group: retinal detachment (2); retinal vein occlusion (1); anterior ischaemic optic neuropathy (1); vitrectomy (26); IOP elevation (20%); cataract surgery (23%) 4-mg group: retinal detachment (4); retinal vein occlusion (2); vitrectomy (19); glaucoma procedures (4); IOP elevation (40%); cataract surgery (51%)</td>
<td>Focal/grid laser is more effective and has fewer side effects than 1 mg or 4 mg triamcinolone</td>
</tr>
<tr>
<td>4 mg + prompt laser</td>
<td>Phase III RCT; 1 yr &amp; 2 yr; 186 eyes (29)</td>
<td>DMO with VA 78–24 letters (20/32–20/320), OCT CST ≥ 250 μm</td>
<td>Median no. of injections: 1 yr (3), 2 yr (4); median no. of laser: 2 yr (3); laser by 48 wk: 21%</td>
<td>Median change in CST: 1 yr (−90 μm), 2 yr (−96 μm); CST &lt; 250 μm and ≥ 25 μm; reduction: 1 yr (47%), 2 yr (45%); median change in VA letters: 1 yr (+5), 2 yr (+6); gain ≥ 15 letters: 1 yr (21%), 2 yr (22%); loss ≥ 15 letters: 1 yr (8%), 2 yr (13%); DR progression at 1 yr: improved (38%), worsened (6%)</td>
<td>2 yr: pseudoendophthalmitis (1%); Effective in pseudophakics but frequently increases the risk of IOP elevation</td>
<td></td>
</tr>
<tr>
<td>4 mg + focal/grid laser + PRP</td>
<td>Phase III study; 14 wk; 109 eyes (24)</td>
<td>DMO with severe NPDR or PDR; VA ≥ 24 letters (≥ 20/320); OCT CST ≥ 250 μm; receiving PRP</td>
<td>Additional PRP: 23%; additional DMO Rx: 42%*</td>
<td>Median change in CST: −75 μm*; CST &lt; 250 μm and ≥ 25 μm reduction: 27%; median change in VA letters: +1*; gain ≥ 15 letters: 10%; loss ≥ 15 letters: 3%</td>
<td>56 wk: endophthalmitis (0); retinal detachment (1); vitrectomy (7); vitreous haemorrhage (31); IOP elevation (30); glaucoma surgery (1); cataract surgery (6)</td>
<td>The addition of one intravitreal triamcinolone injection can reduce short-term exacerbation of DMO and associated VA loss after PRP in eyes that are also receiving focal/grid laser</td>
</tr>
<tr>
<td>Ranibizumab</td>
<td>Phase III RCT; 0.5 mg + prompt laser &amp; 0.5 mg + deferred laser; 187 eyes; 0.5 mg + delayed laser: 188 eyes (22)</td>
<td>DMO with VA 78–24 letters (20/32–20/320), OCT CST ≥ 250 μm</td>
<td>0.5 mg + prompt laser: median no. of injections: 1 yr (8), 2 yr (11); median no. of laser: 2 yr (2); laser by 48 wk: 16%; 0.5 mg + deferred laser: median no. of injections: 1 yr (9); 0.5 mg + prompt laser: median change in CST: 1 yr (−112 μm), 2 yr (−113 μm); CST &lt; 250 μm and ≥ 25 μm; reduction: 1 yr (53%), 2 yr (54%)<em>; median change in VA letters: 1 yr (+10)</em>, 2 yr (+8); gain ≥ 15 letters: 1 yr (30%), 2 yr (29%)<em>; loss ≥ 15 letters: 1 yr (2%), 2 yr (4%)</em>; DR progression at 1 yr: improved (53%), worsened (4%)</td>
<td>0.5 mg + prompt laser: 2 yr: endophthalmitis (1%); ocular vascular event (2%); vitrectomy (2%); vitreous haemorrhage (3%); elevation of IOP/glaucoma (11%); glaucoma surgery (1%); cataract surgery (12%)</td>
<td>Recommended in DMO whether with deferred or prompt laser; endophthalmitis is uncommon, but there is a theoretical risk of increased traction retinal detachments in PDR</td>
<td></td>
</tr>
<tr>
<td>Treatment modality</td>
<td>Study design</td>
<td>Participants</td>
<td>Re-treatment</td>
<td>Outcome</td>
<td>Adverse effects</td>
<td>Authors’ comments</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>---------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0.5 mg at 0 + 4 wk + focal/grid laser + PRP</td>
<td>Phase III study; 14 wk; 113 eyes&lt;sup&gt;(24)&lt;/sup&gt;</td>
<td>DMO with severe NPDR or PDR, VA ≥ 24 letters (≥ 20/320), OCT CST ≥ 250 μm, receiving PRP</td>
<td>Additional PRP: 19%; additional DMO Rx: 44%*</td>
<td>Median change in CST: −26 μm*; CST &lt; 250 μm and ≥ 25 μm reduction: 17%; median change in VA letters: +2*; gain ≥ 15 letters: 7%; loss ≥ 15 letters: 7%</td>
<td>0.5 mg + deferred laser: 2 yr: endophthalmitis (1%); ocular vascular event (2%); retinal detachment (1%); vitreectomy (4%); vitreous haemorrhage (4%); elevation of IOP/glaucoma (7%); glaucoma surgery (0); cataract surgery (13%)</td>
<td>The addition of two intravitreal ranibizumab injections can reduce short-term exacerbation of DMO and associated VA loss after PRP, in eyes also receiving focal/grid laser</td>
</tr>
<tr>
<td>Vitrectomy</td>
<td>Standard pars plana vitrectomy without concomitant cataract extraction</td>
<td>Observational; 6 mth; 87 eyes&lt;sup&gt;(34)&lt;/sup&gt;</td>
<td>Vitreomacular traction as indication; VA 19–63 letters (20/400–20.63), OCT CST &gt; 300 μm</td>
<td>Additional PRP (0); macular laser (4); intravitreal corticosteroid (2); anti-VEGF (2)</td>
<td>Median change in CST: 3 mth &amp; 6 mth (~160 μm)*; CST &lt; 250 μm: 43%; median VA: 3 mth (20/100), 6 mth (20/100); gain ≥ 15 letters: 3 mth (22%), 6 mth (38%); loss ≥ 15 letters: 3 mth (23%), 6 mth (22%)</td>
<td>Vitreous haemorrhage (6%); retinal detachment (3%); endophthalmitis (1%); IOP elevation (8%); cataract surgery within 1 yr (46%)</td>
</tr>
</tbody>
</table>

*Significant at p < 0.05 when compared with standard of care. CST was measured using OCT. CST: central subfield thickness; IOP: intraocular pressure; mETDRS: modified Early Treatment Diabetic Retinopathy Study; NPDR: non-proliferative diabetic retinopathy; OCT: optical coherence tomography; PDR: proliferative diabetic retinopathy; PRP: panretinal photocoagulation; RCT: randomised control trial; VA: visual acuity; VEGF: vascular endothelial growth factor